Personalizing therapy in type 2 diabetes

New study suggests renoprotective effect of SGLT2 inhibitor

In a clinical trial of patients with type 2 diabetes, Hiddo Heerspink and others showed that canagliflozin (a sodium-glucose cotransporter 2 inhibitor) slowed kidney function decline to a greater extent than glimepiride (a sulfonylurea). Investigators analyzed data on... read more